Korean Journal of Ophthalmology

The Korean Ophthalmological Society (대한안과학회)
권호 표지
DOI QR코드

DOI QR Code

Eye-Preserving Therapy in Retinoblastoma: Prolonged Primary Chemotherapy Alone or Combined with Local Therapy

  • Shin, Joo-Young (Department of Ophthalmology, Seoul National University College of Medicine) ;
  • Kim, Jeong-Hun (Department of Ophthalmology, Seoul National University College of Medicine) ;
  • Yu, Young-Suk (Department of Ophthalmology, Seoul National University College of Medicine) ;
  • Khwarg, Sang-In (Department of Ophthalmology, Seoul National University College of Medicine) ;
  • Choung, Ho-Kyung (Department of Ophthalmology, Seoul National University College of Medicine) ;
  • Shin, Hee-Young (Department of Pediatrics, Seoul National University) ;
  • Ahn, Hyo-Seop (Department of Pediatrics, Seoul National University)
  • Received : 2009.11.10
  • Accepted : 2010.03.27
  • Published : 2010.08.05
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the efficacy of primary chemotherapy combined with local therapy in the treatment of retinoblastomas not treatable with a single therapeutic method. Methods: We performed a retrospective chart review of 227 patients diagnosed with retinoblastoma. Sixty-five eyes in 52 patients had tumors not treatable with a single therapeutic method and received primary chemotherapy combined with local therapy as needed. Results: Tumor control and eye salvage was achieved in 34 of the 65 eyes; the probability of ocular survival was 46.56% using the Kaplan-Meier method. Forty-three of the 65 eyes were group D or E tumors, in which tumor control and eye salvage was achieved in 16 eyes. Twenty eyes were treated with chemotherapy only, while 28 eyes received one additional modality of local therapy, and 17 eyes received two modalities of local therapy. Of the eyes treated with chemotherapy only, tumor control was achieved in 5 eyes. Conclusions: Primary chemotherapy combined with local therapy can be effective and safe in the treatment of retinoblastomas otherwise untreatable with other therapeutic methods, such as group D and E retinoblastomas. More vigorous treatment with more local therapeutic methods combined may yield even better results.

Keywords

References

  1. Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus 2000;37:134-41.
  2. Gunduz K, Gunalp I, Yalcindag N, et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004;111:1917-24. https://doi.org/10.1016/j.ophtha.2004.04.016
  3. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993;85:1121-8. https://doi.org/10.1093/jnci/85.14.1121
  4. Imhof SM, Mourits MP, Hofman P, et al. Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology 1996;103:263-8. https://doi.org/10.1016/S0161-6420(96)30706-9
  5. Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 1997;15:1183-9. https://doi.org/10.1200/JCO.1997.15.3.1183
  6. Kim JH, Yu YS, Khwarg SI, et al. Clinical result of prolonged primary chemotherapy in retinoblastoma patients. Korean J Ophthalmol 2003;17:35-43. https://doi.org/10.3341/kjo.2003.17.1.35
  7. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963;67:164-72.
  8. Beck MN, Balmer A, Dessing C, et al. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000;18:2881-7. https://doi.org/10.1200/JCO.2000.18.15.2881
  9. Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004;138:329-37. https://doi.org/10.1016/j.ajo.2004.04.032
  10. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657-64. https://doi.org/10.1016/S0002-9394(02)01348-X
  11. Brichard B, De Bruycker JJ, De Potter P, et al. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 2002;38:411-5. https://doi.org/10.1002/mpo.1355
  12. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-8. https://doi.org/10.1001/archopht.1996.01100140530002
  13. Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-56. https://doi.org/10.1001/archopht.1996.01100140548005
  14. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-8. https://doi.org/10.1001/archopht.1996.01100140521001
  15. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997;104:2101-11. https://doi.org/10.1016/S0161-6420(97)30053-0
  16. Shields CL, Mashayekhi A, Demirci H, et al. Practical approach to management of retinoblastoma. Arch Ophthalmol 2004;122:729-35. https://doi.org/10.1001/archopht.122.5.729
  17. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005;18:41-53, viii. https://doi.org/10.1016/j.ohc.2004.11.003
  18. Campinchi R, Lemerle J, Bloch-Michel E, et al. Does chemotherapy have a role in the treatment of retinoblastomas? Bull Soc Ophtalmol Fr 1976;76:17-22.
  19. Wilson MW, Czechonska G, Finger PT, et al. Chemotherapy for eye cancer. Surv Ophthalmol 2001;45:416-44. https://doi.org/10.1016/S0039-6257(00)00210-1
  20. Pratt CB. Topical topic: use of chemotherapy for retinoblastoma. Med Pediatr Oncol 1998;31:531-3. https://doi.org/10.1002/(SICI)1096-911X(199812)31:6<531::AID-MPO15>3.0.CO;2-F
  21. Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999;36:8-18.
  22. Cohen VM, Kingston J, Hungerford JL. The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol 2009;93:887-90. https://doi.org/10.1136/bjo.2008.142679
  23. Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009;116:544-51.e1 https://doi.org/10.1016/j.ophtha.2008.10.014

Cited by

  1. Clinical Efficacy and Prognostic Factors of Chemoreduction Combined with Topical Treatment for Advanced Intraocular Retinoblastoma vol.15, pp.18, 2014, https://doi.org/10.7314/apjcp.2014.15.18.7805
  2. Retinoblastoma: Evidence for Stage-based Chemotherapy vol.55, pp.1, 2015, https://doi.org/10.1097/iio.0000000000000054
  3. Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma vol.11, pp.1, 2010, https://doi.org/10.1371/journal.pone.0146582
  4. Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis vol.101, pp.1, 2010, https://doi.org/10.1136/bjophthalmol-2016-309710
  5. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis vol.18, pp.None, 2010, https://doi.org/10.1186/s12885-018-4406-6
  6. Targeting tyrosine kinases for treatment of ocular tumors vol.42, pp.4, 2010, https://doi.org/10.1007/s12272-018-1094-3
  7. Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma vol.85, pp.4, 2010, https://doi.org/10.1007/s00280-020-04036-w
  8. Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy vol.35, pp.1, 2010, https://doi.org/10.3341/kjo.2020.0115
  9. Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis vol.13, pp.9, 2021, https://doi.org/10.3390/cancers13092216
  10. Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG) vol.13, pp.14, 2010, https://doi.org/10.3390/cancers13143392